Related Experiment Videos
Sympathetic activation and the role of beta-blockers in chronic heart failure
1Clinical Pharmacology Unit, Monash University, Alfred Hospital, Melbourne, Vic.
Insights
Beta-blockers improve outcomes in chronic heart failure (CHF) by blocking sympathetic nervous system activation. Careful titration and long-term use of these agents, particularly non-selective ones, are key to managing CHF progression and mortality.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) involves sympathetic nervous system activation, which offers short-term support but is detrimental long-term.
- This chronic catecholamine excess contributes to disease progression and mortality in CHF patients.
Purpose of the Study:
- To evaluate the role of sympathetic blockade in managing systolic CHF.
- To review the efficacy of beta-blockers in improving hemodynamic, functional, and mortality outcomes in CHF.
Main Methods:
- Review of studies on beta-blocker therapy in symptomatic CHF (NYHA Class II-III).
- Analysis of the impact of carefully titrated, long-term beta-blocker use.
- Examination of the role of non-selective beta-adrenoceptor blocking drugs.
Main Results:
- Beta-blocker therapy, when carefully up-titrated and used for 3-4 months, improves long-term hemodynamic, functional, and mortality outcomes in CHF.
- Beta-blockers delay CHF progression by reversing myocardial remodeling.
- Non-selective beta-blockers may offer particular benefits due to less downregulation of beta2 receptors.
Conclusions:
- Blockade of sympathetic activation, particularly with beta-blockers, is a crucial strategy for managing CHF.
- Further research is needed for NYHA Class IV patients, post-myocardial infarction heart failure, and asymptomatic left ventricular dysfunction.
Abstract:
Chronic heart failure (CHF) is associated with activation of the sympathetic nervous system. This activation provides short term haemodynamic support to the failing myocardium, but may be deleterious over longer periods as chronic catecholamine excess appears to contribute to disease progression and increased mortality in this condition. Therefore, blockade of sympathetic activation represents a logical, if somewhat counter-intuitive, approach to the management of the patient with systolic CHF. Pharmacological approaches to blockade of this system include inhibition of central sympathetic outflow (using central sympatholytics, e.g. rilmenidine, moxonidine), blockade of the catecholamine biosynthetic pathway (dopamine beta hydroxylase antagonists) and blockade of the cardiac effects of sympathetic activation (beta-adrenoceptor blocking agents). Beta-blockers have now been extensively studied in patients with symptomatic CHF of the New York Heart Association (NYHA) Class II and III severity. Provided beta-blocker therapy is carefully up-titrated from sub-therapeutic doses and given for at least three to four months, these agents have been associated with favourable long term haemodynamic, functional and mortality outcomes. Furthermore, beta-blockers delay disease progression in CHF by reversing the pathological myocardial remodelling process that accompanies the disease. Non-selective beta-adrenoceptor blocking drugs appear to be of particular benefit in CHF therapy. Myocardial beta2 receptors are down-regulated to a lesser extent than beta1 receptors in CHF, therefore blockade of the beta2 receptor sub-type may assume greater importance in inhibiting the deleterious effects of sympathetic activation on the myocardium in this disease. Newer agents that possess additional vasodilator properties (carvedilol, bucindolol, nebivolol) may be useful in overcoming the initial negative inotropy of the beta-blocking component of the drug, however, it is unlikely that vasodilation contributes greatly to long term clinical benefits. Drugs such as carvedilol are also anti-oxidant, anti-proliferative and have anti-endothelin actions; the clinical significance of these properties is yet to be determined. Unanswered questions remain regarding the use of beta-blockers in heart failure. Ongoing studies are further examining mechanisms underlying the clinical benefits of these agents as well as their therapeutic potential in NYHA Class IV patients, heart failure post-myocardial infarction and patients with asymptomatic left ventricular dysfunction.